Valvular Heart Disease — Nursing Assessment Framework
Systematic assessment integrating anatomy, auscultation, investigations, and functional classification.
Cardiac Valve Anatomy Overview
| Valve | Location | Leaflets | Function |
|---|---|---|---|
| Aortic | LV outflow | 3 (bicuspid: 2) | Prevents aortic regurgitation |
| Mitral | LA → LV | 2 (anterior/posterior) | Prevents mitral regurgitation |
| Tricuspid | RA → RV | 3 | Prevents tricuspid regurgitation |
| Pulmonary | RV outflow | 3 | Prevents pulmonary regurgitation |
Stenosis vs Regurgitation
Stenosis
Valve does NOT open fully
Obstruction to forward flow
Pressure overload upstream
Obstruction to forward flow
Pressure overload upstream
Regurgitation
Valve does NOT close fully
Backward / retrograde flow
Volume overload upstream
Backward / retrograde flow
Volume overload upstream
Heart Murmur Assessment — Systematic Approach
Timing in Cardiac Cycle
- Systolic: Between S1 and S2 — Aortic/Pulmonary Stenosis, Mitral/Tricuspid Regurgitation
- Diastolic: Between S2 and S1 — Aortic/Pulmonary Regurgitation, Mitral/Tricuspid Stenosis
- Continuous: Throughout — PDA, AV fistula
- Systolic ejection: Crescendo-decrescendo — AS pattern
- Holosystolic: Constant intensity — MR pattern
Grading Scale (Levine 1–6)
- Grade 1: Very faint — only heard in quiet room, experience required
- Grade 2: Soft but easily audible
- Grade 3: Moderately loud — no thrill
- Grade 4: Loud — palpable thrill
- Grade 5: Very loud — heard with stethoscope lightly applied
- Grade 6: Audible without stethoscope
Radiation Patterns
- Aortic stenosis: Radiates to carotids and right clavicle (harsh ejection)
- Mitral regurgitation: Radiates to axilla (pansystolic)
- Aortic regurgitation: Left sternal edge, Erb's point (decrescendo)
- MVP click-murmur: Apex, may radiate to axilla
Auscultation Positions
- Aortic area: 2nd ICS right sternal border
- Pulmonary area: 2nd ICS left sternal border
- Tricuspid area: 4th ICS left sternal border
- Mitral (apex): 5th ICS midclavicular line
- Erb's point: 3rd ICS left sternal border — AR
Auscultation Manoeuvres
| Manoeuvre | Effect | Murmur Change |
|---|---|---|
| Valsalva (strain phase) | Decreases preload/afterload | MVP click moves earlier; HOCM louder; AS softer |
| Squatting | Increases preload + afterload | AS louder; MVP click delayed; HOCM softer |
| Left lateral decubitus | Brings apex closer to chest wall | Mitral murmurs enhanced (MS/MR) |
| Leaning forward | Brings aortic area forward | Aortic regurgitation — diastolic murmur enhanced |
| Inspiration | Increases right-sided filling | Right-sided murmurs louder (Carvallo sign for TR) |
ECG Findings in Valve Disease
| Finding | Significance | Associated Valve |
|---|---|---|
| LVH (R in V5/V6 >25mm) | Pressure/volume overload LV | Severe AS, AR, MR |
| LAE (P mitrale — broad bifid P) | Left atrial enlargement | Mitral stenosis, MR |
| Atrial Fibrillation | AF highly associated with severe valve disease | Mitral stenosis (most common), MR, severe AS |
| LBBB | Conduction system disease / post-TAVI | Post-TAVI (new LBBB common) |
| Complete Heart Block | Emergency — pacemaker urgently | Post-TAVI (paravalvular), surgical AVR |
| RVH (right axis, dominant R V1) | Pulmonary hypertension 2° to valve disease | Severe MS, severe MR |
Echocardiography Parameters — Key Values
| Parameter | Normal | Abnormal / Severe |
|---|---|---|
| AVA (Aortic Valve Area) | >2.0 cm² | Severe <1.0 cm²; Very severe <0.6 cm² |
| Mean AV Gradient | <10 mmHg | Severe >40 mmHg |
| Peak AV Velocity | <2.0 m/s | Severe >4.0 m/s |
| MVA (Mitral Valve Area) | 4–6 cm² | Severe <1.0 cm²; <1.5 cm² = significant |
| Mitral Mean Gradient | <3 mmHg | Severe >10 mmHg |
| LVEF | 55–70% | <50% = reduced (action threshold for surgery) |
| LV End-Systolic Diameter | <35 mm | >40 mm = surgery threshold (MR) |
NYHA Functional Classification
Class I
No symptoms with ordinary activity. No limitation. Cardiac disease present but no functional impairment.
Class II
Slight limitation. Comfortable at rest. Symptoms with ordinary activity (climbing stairs, moderate exertion).
Class III
Marked limitation. Comfortable at rest. Symptoms with less than ordinary activity (getting dressed, walking on flat).
Class IV
Symptoms at rest. Any physical activity increases discomfort. Bedridden or chair-bound.
BNP / NT-proBNP in Valve Disease
- BNP released from ventricular myocardium in response to wall stress and volume overload
- Elevated in severe AS, severe MR, heart failure from valve disease
- BNP >50 pg/mL or NT-proBNP >125 pg/mL — heart failure screening threshold
- Serial BNP monitoring: rising trend in asymptomatic severe AS indicates deterioration
- NT-proBNP >3x upper normal limit in asymptomatic severe AS — consider early intervention (ESC 2021 Class IIa)
- Post-TAVI/AVR: BNP should fall — persistent elevation suggests incomplete decompression
- Renal impairment elevates BNP — common in GCC patients with diabetes/hypertension
Cardiac Catheterisation — Nursing Role
Pre-Procedure Preparation
- Consent obtained and documented (interpreter if needed)
- Fasting 4–6 hours (clear fluids to 2h) — confirm
- Renal function (creatinine/eGFR) — contrast nephropathy risk
- Metformin withheld 24–48h if eGFR <45
- Anticoagulation: warfarin held per protocol; bridging if high risk
- Iodine/contrast allergy screen; pre-medication if history
- Mark peripheral pulses bilaterally (for post-procedure comparison)
- IV access, baseline ECG, consent for sedation
Post-Procedure Care
- Groin/wrist compression per operator instruction (radial: 2h TR Band; femoral: 4–6h bed rest)
- Neurovascular observations: 15min × 4, 30min × 2, hourly × 2
- Monitor for: haematoma, haemorrhage, distal ischaemia, vagal reaction
- Hydration: 500–1000 mL IV post-procedure for contrast clearance
- Urine output monitoring (contrast nephropathy — creatinine at 48h)
- ECG post-procedure — monitor for dysrhythmia
Aortic Stenosis — Comprehensive Nursing Guide
Most common valvular heart disease in developed world. Increasing prevalence in GCC with ageing population and congenital bicuspid aortic valve.
Pathophysiology
Calcific Degenerative AS (Most Common — Elderly)
- Progressive calcium deposition on valve leaflets
- Risk factors: Age >65, male sex, hypertension, dyslipidaemia, diabetes, smoking
- Similar pathology to atherosclerosis — lipid infiltration, inflammation, calcification
- GCC: accelerated by metabolic syndrome and diabetes epidemic
Bicuspid Aortic Valve (BAV)
- Congenital — 2 leaflets instead of 3 (1–2% population)
- Higher prevalence in consanguineous populations (relevant in GCC)
- Develops AS 10–20 years earlier than tricuspid valve
- Associated: aortic root dilation, coarctation, aortic dissection risk
- Surveillance: Echo every 3–5 years if no significant valve disease
AVA Severity Classification
Mild
AVA >1.5 cm²
Gradient <20 mmHg
Vel <3 m/s
Vel <3 m/s
Moderate
1.0–1.5 cm²
Gradient 20–40 mmHg
Vel 3–4 m/s
Vel 3–4 m/s
Severe
AVA <1.0 cm²
Gradient >40 mmHg
Vel >4 m/s
Vel >4 m/s
Very Severe
AVA <0.6 cm²
Gradient >60 mmHg
Vel >5 m/s
Vel >5 m/s
Low-flow, low-gradient AS (EF <40%): AVA may appear severe but gradient low. Dobutamine stress echo required to differentiate true severe AS from pseudo-severe AS.
Classic Triad of Severe Aortic Stenosis — Prognosis Without Intervention
💔
Angina
~5 years
Median survival without AVR
Subendocardial ischaemia — fixed obstructed outflow cannot meet demand
🔄
Syncope
~3 years
Median survival without AVR
Exertional — fixed CO, vasodilatation during exercise → cerebral hypoperfusion
🫁
Dyspnoea / HF
~2 years
Median survival without AVR
LV decompensation — diastolic then systolic failure — worst prognosis of the triad
KEY NURSING ALERT: Any symptom onset in a patient with known severe AS = urgent cardiology referral. Symptom onset marks transition from compensated to decompensated disease. Risk of sudden cardiac death increases significantly.
Medical Management of Aortic Stenosis
Important: No medication has been proven to slow progression of aortic stenosis. Management is largely symptom-based until valve intervention.
Symptom Management
- Heart failure: cautious diuretics (avoid over-diuresis — preload dependent)
- AF: rate control (digoxin, beta-blocker if tolerated) — cardioversion if new AF
- Hypertension: treat cautiously — avoid large drops in BP; ACEi/ARB if HF with reduced EF
- Statins: do NOT slow AS progression (SEAS/SALTIRE trials) but treat dyslipidaemia for CV risk
- Avoid: vasodilators (nitrates, alpha-blockers) — can cause severe hypotension
- Avoid: aggressive diuresis — LV outflow obstruction is preload-dependent
- Antibiotic prophylaxis: only if prior infective endocarditis history (NOT routine dental)
AVR Indications (ESC 2021)
Intervention Indicated (Class I)
- Severe AS + symptoms (angina, syncope, dyspnoea — any)
- Severe AS + LVEF <50% (even if asymptomatic)
- Severe AS undergoing other cardiac surgery (CABG, aortic surgery)
Intervention Reasonable (Class IIa)
- Very severe AS (AVA <0.6 cm²) + asymptomatic + low surgical risk
- Asymptomatic severe AS + NT-proBNP >3× upper normal + confirmed not from other cause
- Asymptomatic severe AS + exercise test: symptoms or drop in BP >20 mmHg
- Asymptomatic severe AS + LVEF 50–55% (borderline)
TAVI vs SAVR Decision Factors
| Factor | Favours TAVI | Favours SAVR |
|---|---|---|
| Age | >75 years | <65 years |
| STS Score | >8% (high risk) | <4% (low risk) |
| Frailty | Moderate–severe | None/minimal |
| Anatomy | Suitable femoral access | Bicuspid, heavy calcification |
| Concomitant disease | Severe COPD, liver disease | CAD needing CABG |
| Longevity concern | Limited life expectancy | Long life expectancy (durability) |
Interactive Tool: Aortic Stenosis Severity Classifier
Enter echocardiographic parameters to classify AS severity and generate clinical recommendations.
TAVI — Transcatheter Aortic Valve Implantation Nursing
Comprehensive perioperative nursing guide for TAVI patients across pre-procedural assessment, intra-procedural support, and post-TAVI monitoring.
Pre-TAVI Assessment — Nursing Responsibilities
Mandatory Pre-TAVI Investigations
- CT Angiography (CTA): Aortic root sizing, access route planning, annular dimensions — ensure patient has renal function checked before IV contrast
- Coronary Angiography: Exclude significant CAD needing revascularisation before TAVI
- TOE (Transoesophageal Echo): Detailed valve morphology, subvalvular anatomy, annular measurement
- TTE (Transthoracic Echo): Baseline LVEF, gradient confirmation, LV dimensions
- Frailty Assessment: Clinical frailty scale, 5-metre walk test, grip strength
- Bloods: FBC, U&E, creatinine, coagulation, group and screen, HbA1c
- Dental Review: Oral hygiene optimised — endocarditis risk post-TAVI
Access Route Assessment
| Route | Requirements | Complications |
|---|---|---|
| Transfemoral | Femoral artery >6mm, no severe calcification/tortuosity — preferred (80%+) | Vascular access site complications, haematoma, retroperitoneal haemorrhage |
| Trans-subclavian | Left subclavian artery access — when femoral not suitable | Brachial plexus injury, subclavian haematoma |
| Transapical | LV apex access via thoracotomy — surgical hybrid | Apical haemorrhage, pleural effusion, higher morbidity |
| Trans-aortic | Direct aortic access via mini-sternotomy | Higher surgical risk, less common |
Anaesthesia Options
- Local + conscious sedation: Preferred for transfemoral — faster recovery, less ICU time
- General anaesthesia: Transapical, anxious patients, haemodynamic instability risk
- TOE guidance: Requires GA or deep sedation for probe insertion
Day of Procedure — Cath Lab Nursing Preparation
Pre-Procedure Checklist
- Patient identification and consent verified (3-way check)
- Fasting confirmed — 4h for solids, 2h for clear fluids
- Baseline vital signs, weight, ECG documented
- IV access ×2 (large bore 14–16G) — one dedicated for emergency drugs
- Arterial line (radial — invasive BP monitoring throughout)
- Urinary catheter — urine output monitoring, prevent movement during procedure
- Bilateral groin prep and drape (left femoral — temporary pacemaker; right femoral — valve delivery)
- Defibrillator pads applied — padded on back and anterior chest
- Emergency drugs prepared: atropine, vasopressin, adrenaline, protamine
- Antibiotics administered per protocol (cefazolin 2g IV or allergy alternative)
Intra-Procedural Monitoring
- Continuous ECG — operator alerted to any rhythm change immediately
- Invasive arterial BP every beat — mean BP target >65 mmHg
- Temporary transvenous pacemaker (RV apex) — standby 80–100 bpm for rapid pacing during deployment
- Rapid pacing during valve deployment: 180–220 bpm → BP drop → stabilises position
- Fluoroscopy and echo (TTE/TOE) guidance — co-ordinate with cardiac sonographer
- Contrast injections — track cumulative contrast volume (nephropathy risk)
- Post-deployment echo assessment: gradient, paravalvular leak, pericardial effusion
- ACT monitoring — heparin 70–100 U/kg; target ACT 250–300 seconds
Post-TAVI Monitoring — Critical Nursing Priorities
Vascular Access Site Complications
- Groin haematoma: Most common — monitor size, mark borders with pen, apply pressure if expanding
- Retroperitoneal haemorrhage: Back/flank pain, hypotension, fall in Hb — CT abdomen urgent if suspected
- Pseudoaneurysm: Pulsatile groin mass — ultrasound guided compression or thrombin injection
- Arterial occlusion: Loss of distal pulses — vascular surgery emergency
- Neurovascular observations every 15 min ×4, then 30 min ×4, then hourly
- Bilateral lower limb pulses, colour, warmth, capillary refill, sensation
Cardiac Rhythm (CRITICAL)
Complete Heart Block: Occurs in 5–25% of TAVI. LBBB most common (20–30%). If CHB occurs: activate temporary pacemaker immediately. New LBBB monitoring 48–72h — PPM implantation if persists.
- Continuous ECG monitoring minimum 48–72 hours post-TAVI
- New LBBB: PR interval monitoring, watch for progression to CHB
- Temporary pacemaker: maintain backup rate 40–50 until assessed; check threshold daily
- Late CHB can occur up to 7 days — educate patient on symptoms (presyncope, dizzy)
Stroke Risk (24–72 hours)
Stroke risk highest in first 72h post-TAVI (2–4%). Calcium/debris embolisation during valve deployment. NIHSS or MRS baseline documented pre-TAVI.
- Neurological observations hourly ×12, then 4-hourly ×48h
- FAST assessment at each observation — Face/Arms/Speech/Time
- New confusion, facial droop, weakness, speech — stroke team immediate activation
- CT head non-contrast if stroke suspected
- Cerebral embolic protection device used in some centres — document if used
Other Post-TAVI Concerns
- Device malposition/embolisation: Valve migration into aorta or LV — surgical emergency; rare (<1%)
- Paravalvular leak (PVL): AR jet around valve — mild acceptable; moderate/severe requires intervention
- Coronary obstruction: Chest pain/ST changes post-deployment — cath lab re-activation
- Pericardial tamponade: Hypotension + jugular distension — echo immediately, pericardiocentesis
- Acute kidney injury: Monitor hourly urine output, creatinine at 24/48h
Early Mobilisation & Discharge
- Transfemoral with closure device: mobilise same day or day 1
- Transapical: day 2–3 mobilisation (thoracotomy wound)
- DAPT: Aspirin 75–100mg indefinitely + Clopidogrel 75mg for 3–6 months
- Echo before discharge — confirm gradient and rule out PVL
- Cardiac rehab referral — structured programme improves outcomes
Mitral Valve Disease — Nursing Guide
Mitral stenosis remains highly prevalent in GCC due to rheumatic fever burden in migrant worker populations. Mitral regurgitation includes primary structural and secondary functional causes.
Mitral Stenosis (MS)
Aetiology & Pathophysiology
- Rheumatic fever — predominant cause globally and in GCC migrant population
- Group A Strep pharyngitis → untreated → rheumatic fever → valve inflammation → fibrosis/fusion
- Leaflet tip fusion, subvalvular apparatus thickening, calcification over years/decades
- GCC: high prevalence in South Asian and African migrant workers with prior rheumatic fever
- Congenital MS: rare, presents in childhood
- Mitral annular calcification: elderly, contributes to functional MS
MVA Severity Classification
Mild
MVA >1.5 cm²
Gradient <5 mmHg
Moderate
1.0–1.5 cm²
Gradient 5–10 mmHg
Severe
MVA <1.0 cm²
Gradient >10 mmHg | Wilkins score guides intervention
Complications of Mitral Stenosis
- Atrial Fibrillation: LA dilation → AF. Occurs in 40–75% of symptomatic MS. Rate control + anticoagulation essential.
- Systemic thromboembolism: LA thrombus — AF + MS = high stroke risk. Warfarin (target INR 2–3)
- Pulmonary hypertension: Chronic high LA pressure → pulmonary vascular remodelling → RHF
- Pulmonary oedema: Acute deterioration — pregnancy, AF with fast ventricular rate, exercise, fever
- Haemoptysis: Rupture of bronchial veins engorged from pulmonary hypertension
- Infective endocarditis: Less common than regurgitant lesions but possible
AF Management in MS
- All MS patients with AF: anticoagulation regardless of CHA2DS2-VASc score
- Warfarin preferred over DOACs (mitral stenosis AF excluded from DOAC trials)
- Target INR 2–3 (or 2.5–3.5 if high thromboembolic risk)
- Rate control: beta-blocker, digoxin, or combination
- Rhythm control: only after LA thrombus excluded by TOE
Percutaneous Mitral Balloon Valvotomy (PMBV) — Wilkins Score
Wilkins score assesses suitability for PMBV (balloon dilation of fused mitral leaflets). Score ≤8 = good candidate. Each criterion scored 1–4:
- Leaflet mobility (1=highly mobile to 4=minimal motion)
- Leaflet thickening (1=near normal to 4=severe thickening)
- Subvalvular thickening (1=minimal to 4=extensive)
- Calcification (1=single area to 4=extensive)
PMBV Nursing Care
- Pre: TOE to exclude LA thrombus (absolute contraindication), INR <2 on day of procedure
- During: femoral venous access, trans-septal puncture, balloon inflation across MV
- Post: echo immediately — confirm MVA improvement, check for MR (complication)
- Complication watch: severe MR (chordal tear/leaflet tear), stroke (LA thrombus), cardiac tamponade (septal puncture), ASD
- PMBV avoids open heart surgery — highly preferred in suitable GCC rheumatic MS patients
Mitral Regurgitation (MR)
Primary (Organic) MR — Structural
- Mitral Valve Prolapse (MVP): Most common cause in developed world — myxomatous degeneration, leaflet billowing into LA during systole
- Ruptured Chordae Tendineae: Spontaneous or post-IE — acute severe MR, pulmonary oedema
- Infective Endocarditis: Vegetation, leaflet perforation, chordal destruction
- Rheumatic: Leaflet scarring/retraction — mixed MS/MR common
- Congenital: Cleft leaflet (associated with ASD primum)
Secondary (Functional) MR
- Normal mitral leaflets — problem is LV geometry/function
- LV dilation (dilated cardiomyopathy, ischaemic) → papillary muscle displacement → incomplete leaflet coaptation
- Ischaemic MR: post-MI papillary muscle dysfunction or rupture
- Treatment targets underlying LV disease (HF therapy, revascularisation)
Acute Severe MR — Emergency
EMERGENCY: Acute MR (ruptured papillary muscle post-MI or ruptured chordae) = cardiogenic shock. LV not adapted to sudden volume overload → acute pulmonary oedema + hypotension.
- Presentation: acute onset pulmonary oedema, hypotension, new pansystolic murmur post-MI
- Immediate: ITU admission, mechanical ventilation likely, vasopressors
- IABP (Intra-Aortic Balloon Pump): Bridge to surgery — reduces afterload, improves CO
- Definitive: Emergency surgical mitral valve repair or replacement
- Mortality without surgery: >50% in-hospital
- Nursing: invasive monitoring (arterial line, CVC, PA catheter), hourly urine, IABP management
Chronic MR — Watchful Waiting Thresholds
Surgery for chronic primary MR indicated when LV begins to decompensate — act before irreversible LV dysfunction.
- Symptoms (NYHA II-IV) with severe MR → surgery
- Asymptomatic severe MR + LVEF <60% → surgery (EF falsely elevated in MR — 60% here = significant dysfunction)
- Asymptomatic severe MR + LV end-systolic diameter >40 mm → surgery
- New AF or pulmonary hypertension (sPAP >50 mmHg) with severe MR → consider surgery
- Surveillance echo: every 6–12 months if watching asymptomatic severe MR
MitraClip — Percutaneous Mitral Repair
- Catheter-based edge-to-edge mitral repair — clips anterior and posterior leaflet together
- Indicated: high surgical risk patients with severe primary or secondary MR
- Trans-septal approach under TOE guidance — no sternotomy required
- Pre-procedure: TOE anatomy assessment (leaflet morphology, gap size, coaptation length)
- Post-procedure: echo confirmation of MR reduction, access site monitoring
- COAPT trial: MitraClip in secondary MR + HF → reduced HF hospitalisations and mortality
- GCC programmes: available at SKMC Abu Dhabi, Cleveland Clinic Abu Dhabi, KFSH Riyadh
Prosthetic Heart Valve Nursing
Lifelong nursing support for patients with mechanical or bioprosthetic valves — anticoagulation management, complication monitoring, and education.
Mechanical vs Bioprosthetic Valves
| Feature | Mechanical | Bioprosthetic (Tissue) |
|---|---|---|
| Durability | 30+ years (lifetime) | 10–20 years (structural deterioration) |
| Anticoagulation | Lifelong warfarin (mandatory) | 3 months warfarin or aspirin only (long-term) |
| Thromboembolic risk | Higher without anticoagulation | Lower baseline risk |
| Patient preference | Avoids re-operation (if compliant with warfarin) | Avoid lifelong anticoagulation |
| Preferred in | Age <60, good compliance, no bleeding risk | Age >65, poor compliance, bleeding risk, women planning pregnancy |
| Sound | Audible mechanical click | Silent — similar to native valve |
Warfarin Target INR by Valve Type
Mechanical Aortic
INR 2.0–3.0
+ Aspirin 75mg if additional risk factors
Mechanical Mitral
INR 2.5–3.5
Higher target — more thrombogenic position
Bioprosthetic (First 3M)
INR 2.0–3.0
First 3 months while endothelialisation occurs
Bioprosthetic (Long-term)
Aspirin 75–100mg
Or continue warfarin if AF/other indication
Warfarin Patient Education — GCC Context
Key Education Points
- Purpose: Prevents blood clots forming on mechanical valve — missing doses is dangerous
- INR testing: Regular blood tests — frequency depends on stability (weekly initially → monthly if stable)
- Self-monitoring: Point-of-care INR device — effective for motivated patients; reduces clinic visits
- Dietary vitamin K consistency: Dark green leafy vegetables (spinach, broccoli, parsley) — not to eliminate but maintain consistent intake
- Drug interactions: NSAIDs, antibiotics, antifungals, herbal medicines — always tell prescriber about warfarin
- Supplements: Vitamin K supplements, turmeric high doses, ginkgo — all interact
- Alcohol: Moderate or avoid — affects warfarin metabolism; binge drinking causes dangerous swings
- Symptoms to report: Unusual bruising, blood in urine/stool, prolonged bleeding, signs of valve thrombosis (acute breathlessness, click change)
Bridging Therapy for Procedures
- Warfarin held 5 days before surgery (target INR <1.5 for procedure)
- High thromboembolic risk (mechanical mitral valve): LMWH/UFH bridging while INR sub-therapeutic
- Low risk (bioprosthetic): may not require bridging — individualised decision
- Resume warfarin evening of or day after surgery when haemostasis adequate
- LMWH continued until INR therapeutic (usually 4–6 days)
- Dental procedures: Continue warfarin if INR <3.0; use tranexamic acid mouthwash locally — do NOT stop warfarin for dental work
DOACs & Mechanical Valves
CONTRAINDICATED: DOACs (apixaban, rivaroxaban, dabigatran) are contraindicated with mechanical heart valves. Dabigatran caused excess valve thrombosis and bleeding in RE-ALIGN trial. Warfarin ONLY for mechanical valves.
Prosthetic Valve Complications — Nursing Recognition
| Complication | Signs & Symptoms | Nursing Action |
|---|---|---|
| Valve Thrombosis | Mechanical — acute breathlessness, loss of metallic click, hypotension, new murmur, embolic event | EMERGENCY: ITU. Urgent TOE/echo. Thrombolysis (small non-obstructive thrombus) or emergency surgery (obstructive). Subtherapeutic INR often precipitant. |
| Haemolysis | Haematuria (tea-coloured urine), anaemia, jaundice, fatigue, LDH elevated, haptoglobin low | LDH, haptoglobin, reticulocyte count. Echo for paravalvular leak (most common cause). Iron/folate supplementation. Severe haemolysis → valve reoperation. |
| Structural Deterioration | Bioprosthetic — gradual dyspnoea/symptoms over months-years. Echo: leaflet calcification, increasing gradient, new regurgitation | Serial echo surveillance (annual in bioprosthetic). Plan for redo surgery or Valve-in-Valve TAVI when deterioration confirmed. |
| Infective Endocarditis | FEVER in patient with prosthetic valve = URGENT investigation. New murmur, embolic phenomena, haematuria, splinter haemorrhages, Osler nodes | URGENT: 3 blood culture sets before antibiotics. TOE (superior to TTE for prosthetic valves). Cardiac surgery team early involvement — prosthetic IE often requires surgery. |
| Pannus Formation | Insidious onset over years — increasing gradient on echo. Fibrous ingrowth under valve orifice obstructing prosthesis | Distinguish from thrombus (pannus: gradual, lower INR history; thrombus: acute, subtherapeutic INR). Thrombus responds to thrombolysis; pannus requires surgery. |
| Paravalvular Leak (PVL) | Regurgitant murmur, dyspnoea, haemolysis. May be early (suture dehiscence/IE) or late (tissue erosion) | Echo quantification. Mild: observe. Significant haemolysis or symptoms: percutaneous closure or redo surgery. |
Antibiotic Prophylaxis — Current Guidance (ESC 2023)
Prophylaxis IS Recommended
- Dental procedures involving gingival manipulation — in patients with PRIOR infective endocarditis history
- Dental procedures in patients with prosthetic heart valves (mechanical or bioprosthetic)
- Congenital heart disease (unrepaired cyanotic or repaired with residual defect)
- Cardiac transplant with valvulopathy
- Drug: Amoxicillin 2g oral 30–60 min before; if allergic: Clindamycin 600mg
Prophylaxis NOT Routinely Recommended
- Native valve disease (AS, MR, MS) without prior IE — no prophylaxis for dental procedures
- MVP without prior IE — not routinely recommended
- Gastrointestinal or genitourinary procedures — not recommended even in high-risk patients
Good oral hygiene and regular dental review are more important than prophylactic antibiotics for long-term IE prevention. Educate all prosthetic valve patients.
GCC-Specific Heart Valve Disease Context
Understanding the unique epidemiological, cultural, and healthcare system factors affecting valve disease care across Gulf Cooperation Council countries.
Rheumatic Heart Disease in GCC — Epidemiology
Burden of Disease
- Rheumatic heart disease (RHD) remains a significant public health issue in GCC
- High prevalence in migrant worker populations (South Asia: India, Pakistan, Bangladesh, Sri Lanka; Africa: Egypt, Ethiopia, Sudan)
- Mechanism: Group A Streptococcus pharyngitis → untreated → acute rheumatic fever → carditis → valve scarring
- Mitral stenosis: most common manifestation (~65% of rheumatic valve disease)
- Younger age at presentation compared to Western counterparts (25–45 years vs 60–70 years)
- Many patients arrive in GCC with pre-existing undiagnosed RHD
- Pre-employment medical screening identifies many cases — important nursing role
Rheumatic Fever Prophylaxis
Secondary prophylaxis prevents recurrent ARF and limits further valve damage. Crucial for all patients with documented acute rheumatic fever or established RHD.
- Benzathine penicillin G (BPG): 1.2 million units IM every 3–4 weeks
- Duration: minimum 10 years after last attack, or until age 25 (whichever longer)
- With carditis/valve disease: continue to age 40, or lifelong if high re-exposure risk
- Penicillin allergy: oral erythromycin 250mg BD or azithromycin
- Nursing role: IM injection technique (Z-track for deep IM), patient education on adherence
- GCC challenge: migrant workers on rotating visas — maintaining adherence programme challenging
- WHO and GCC Health Ministries have RHD control programmes — nurse-led injection clinics
Bicuspid Aortic Valve in GCC
- BAV prevalence 1–2% globally — possibly higher in consanguineous populations
- Consanguineous marriage historically more prevalent in GCC Arab populations
- BAV congenital autosomal dominant with incomplete penetrance
- Family screening recommended for first-degree relatives of BAV patients (echo)
- Develops AS and AR earlier than tricuspid aortic valve (often 40s–50s)
- Aortic root/ascending aorta dilation: surveillance CT/MRI aorta annually if >40mm
- TAVI for BAV: technically more challenging — calcification pattern, risk of AR, valve instability. Experienced centre required.
Major Cardiac Surgery Centres in GCC
| Centre | Country | Speciality |
|---|---|---|
| Sheikh Khalifa Medical City (SKMC) | Abu Dhabi, UAE | TAVI, SAVR, MitraClip, complex valve surgery |
| Cleveland Clinic Abu Dhabi | Abu Dhabi, UAE | Structural heart, TAVI, cardiac surgery |
| King Faisal Specialist Hospital (KFSH) | Riyadh, Saudi Arabia | Full cardiac surgery, TAVI, paediatric cardiac |
| King Abdulaziz Medical City | Jeddah, Saudi Arabia | Cardiac surgery, structural heart programme |
| Hamad Medical Corporation | Doha, Qatar | Cardiac surgery, interventional cardiology |
| King Hamad University Hospital | Manama, Bahrain | Cardiac surgery, TAVI programme |
| Royal Hospital | Muscat, Oman | Cardiac surgery, national referral centre |
Ramadan and Warfarin Management — Nursing Guide
Ramadan Challenge: Dietary changes during Ramadan significantly affect vitamin K intake and warfarin stability. GCC nurses must be prepared to provide culturally sensitive guidance.
Why INR Changes During Ramadan
- Dietary pattern shift: large iftar and suhoor meals — different vitamin K content
- Increased intake of green salads, herbs (parsley, coriander), leafy vegetables at iftar
- Dehydration during daylight hours — affects drug distribution
- Changed meal timing affects warfarin absorption timing
- Reduced physical activity (daytime) and altered sleep patterns
- Warfarin timing: recommend taking warfarin at consistent time — iftar or suhoor (same time each day)
Nursing Recommendations for Ramadan
- INR check 1–2 weeks before Ramadan begins (baseline)
- More frequent INR monitoring during Ramadan — every 2 weeks minimum for mechanical valve patients
- Dietary consistency education: avoid dramatically changing green vegetable intake from pre-Ramadan
- Patients physically able to fast may do so — warfarin management permits fasting
- Tablet swallowing with water does NOT break the fast in Islamic scholarship — warfarin permitted
- Contact cardiologist / anticoagulation clinic for dose adjustments
- Post-Ramadan: INR recheck as dietary pattern returns to baseline
Halal Anticoagulants — Religious Considerations
- Warfarin: Synthetic — generally considered halal for medical use. Well-established in GCC Muslim practice.
- DOACs (apixaban, rivaroxaban, dabigatran): Synthetic — halal status clear. However CONTRAINDICATED in mechanical valves.
- Heparin (unfractionated & LMWH): May contain porcine (pig-derived) heparin — this is a concern for Muslim patients. Options: bovine-derived heparin (available in some GCC centres), synthetic fondaparinux (does not contain animal products).
- Scholars generally permit porcine heparin when no halal alternative available and life at risk (darura — necessity).
- Some GCC hospitals stock bovine heparin for Muslim patients — check pharmacy availability.
- Key nursing role: raise question sensitively, involve pharmacist and pastoral care as needed, document patient preference.
Transcatheter Valve Programmes Expanding in GCC
- TAVI volumes growing rapidly across GCC — particularly UAE and Saudi Arabia
- Younger patient age at presentation — structural durability data important
- TAVI registries being established: Saudi Heart Association, Emirates Cardiac Society data
- MitraClip and TMVR (transcatheter mitral valve replacement) programmes emerging
- Nurse specialisation: structural heart nurses / cardiac catheterisation nurses in high demand
- Training programmes: partnership with Cleveland Clinic, Mayo Clinic, European centres
- Valve-in-Valve TAVI growing — bioprosthetic valve failure treated without redo surgery
- Rheumatic valve disease in younger patients: challenging anatomy for TAVI — surgical still preferred
Language & Cultural Communication in GCC Valve Disease Nursing
Multilingual Patient Population
- Arabic: national population — Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman
- Urdu/Hindi: large South Asian migrant workforce
- Tagalog: Filipino healthcare workers and domestic workers
- Tamil/Malayalam: South Indian workers
- Qualified medical interpreters — mandatory for consent and complex education
- Translated patient education materials for warfarin — INR diaries in multiple languages
Cultural Considerations
- Family involvement in decision-making — common in GCC culture; involve family with patient consent
- Gender preferences: female patients may prefer female nurses/doctors — accommodate when possible
- Prayer times: medications and procedures — allow time for prayer; prayer does not conflict with medical care
- Hajj and Umrah pilgrimage: valve patients planning pilgrimage — extreme physical exertion, heat, infection exposure. Pre-pilgrimage cardiac assessment recommended.
- End of life discussions: sensitive topic — involve family, hospital imam/chaplain when appropriate